TSH announces TFDA acceptance Tyrvaya® for Dry Eye Nasal Spray, expected approval by late 2024.

TSH Biopharm has acquired a 51% equity stake in Chuang Yi Biotech, marking it as the first subsidiary under TSH Biopharm.

TSH receives the commercialization support of Tyrvaya® in Taiwan from JIXING Pharmaceuticals and TSH will initiate registration of Tyrvaya®.

Mr. Yang Sze Yuan, General Manager of Easton Pharmaceuticals, received the National Brand Yu Shan Award for Outstanding Corporate Leadership.

Easton Pharmaceuticals received the Taiwan Investor Relations Association's inaugural "Taiwan Investor Relations Award."

The drug "Cretrol tablet" received approval for insurance reimbursement.

The drug "Rhynorm coated tablet" obtained pharmaceutical approval in Hong Kong.

The drug "Amtrel tablet" obtained pharmaceutical approval in Myanmar.

Easton Pharmaceuticals received the HR Asia 2022 Best Companies to Work for in Asia Award.

Easton Pharmaceuticals established a Sustainable Development Committee and formed an ESG (Environmental, Social, Governance) task force.

Easton Pharmaceuticals ranked among the top 5% in the 8th OTC Corporate Governance Evaluation in Taiwan.

The drug "ALPROSM crystal injection" received official pharmaceutical approval for improving symptoms of peripheral artery blockage.

The drug "Cretrol tablet" received official pharmaceutical approval for the treatment of high blood lipids as a new compound drug.

Mr. Yang Sze Yuan, the General Manager of Easton Pharmaceuticals, was honored with the "Top Ten Managers of the Year" award by the Republic of China.
Clinical application technology for circulating tumor cells and circulating tumor DNA received the "Top Ten Enterprises of the Year 2021" award in the Republic of China, which is used for precise drug determination and cancer tracking assistance.

Easton Pharmaceuticals entered into a partnership agreement with NASDAQ-listed company Centogen to provide cancer risk assessment and medication selection for cancer patients (including breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, etc.) in Taiwan. They also offer genetic risk assessment testing for healthy individuals.

Exclusive acquisition of the regional market rights and joint development rights for a bioequivalent medication for osteoporosis (codenamed TRIAS) by Easton Pharmaceuticals, used in the treatment of osteoporosis.

Exclusive acquisition of the Taiwan rights for Alpha-liquid®, a next-generation gene testing (NGS) technology by IMBDx, used for early-stage cancer post-operative monitoring and recurrence detection.

TSH Biopharm launches Guzip’s Mpap Test, a new endometrial cancer screening test

TSH Biopharm awarded for the 16th National Innovation Prize in Entrepreneur Category

TSH sunmitted new drug application (NDA) for RNTA06 to TFDA

TSH Biopharm authorize InnoPharmax reauthorize the third party to commercialize CRTA

The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended, and the result meets the primary endpoint

Invested in the US company CellMax Cayman and signed a distribution contract withits subsidary CellMax Life (hereafter referred to as CellMax Life) to acquire the exclusive commercialization right of all CellMax Life liquid- biopsy diagnosis products and subsequent new products in territory of Taiwan

TuNEX (ENIA or ENIA11 or E11) has been approved by TFDA

TSH sunmitted new drug application (NDA) for CRTA04 to TFDA

The second Phase III clinical trial of E11 (TuNEX) was unblinded

TSH sunmitted new drug application (NDA) for E11 (TuNEX) to TFDA

The first Phase III clinical trial of E11 (TuNEX) was unblinded

The Investigational New Drug (IND) application for E11 (TuNEX) ankylosing spondylitis Phase III clinical study is approved by TFDA

DM07 hypertension treatment indication patent are granted in China, Japan, and Russia

Patient recruitment of E11(TuNEX) phase III clinical study is completed

TSH is granted by Taiwan Corporate Governance Association for CG6009 Company Management Assessment Certification

TRIA11 is granted by Ministry of Economic Affairs A+ Industrial Innovative R&D Fund program for osteoporosis treatment

TSH invests Pharmira Laboratories, Inc. NTD 70 million and obtains 31.82% share

TSH raises NTD 34.9 million and makes Paid-in capital to NT$383 million

TSH ENIA11 is granted by Ministry of Economic Affairs Industrial Technology Development Fund Program for Phase III Clinical Study

TSH initiates ENIA11 PhaseIII Clinical Trial

TSH Amtrel wins 2012 Taipei Biotechnology Commercialization Award

EMTA07 and ENIA11 are named as the Demonstration Projects of DFTA Pharm Development of Taiwan and China Program

TSH Linicor is approved by TFDA for Hyperlipidemia

TSH raises NTD 37.34 million and makes Paid-in capital to NTD 317 million

TSH is approved for OTC (Over the Counter) company

TSH applies for OTC (Over the Counter) company registration

TSH is approved and registered in Emerging stock market list

TSH is approved by Financial Supervisory Commission as Public Offering Stock

TSH raises NTD 30 million and makes Paid-in capital to NTD 280 million

TSH Biopharm spin-off from TTY Biopharm, with a paid-in capital of NT$150 million

Amtrel formulations patent granted

Catilon is launched for the treatment of irritable bowel syndrome

Amtrel is launched for hypotension

Mopride is launched for the treatment of functional dyspepsia

TTH Business Unit is established in TTY Biopharm and focusing on Cardiovascular, Gastrointestinal, and Central nervous system diseases